Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA-IIIB(N2) Previously Resected (R0) Non-small Cell Lung Cancer Patients That Did Not Achieve Pathological Complete Response After Neoadjuvant treatment_ARIAN

NCT06431633 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT06431633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06431633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA-IIIB(N2) Previously Resected (R0) Non-small Cell Lung Cancer Patients That Did Not Achieve Pathological Complete Response After Neoadjuvant treatment_ARIAN
Lead sponsor
Fundación GECP
Phase
Phase 3
Overall status
Recruiting
Start date
February 4, 2025
Completion date
November 30, 2031
Enrollment
129 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, lung diseases, resectable lung non-small cell carcinoma